Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal:: Journal of Clinical Oncology
Published:: 2025-06-07
DOI:: 10.1200/jco-25-00166
Affiliations:: 23
Authors:: 28

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	8.000000	0.29
State Key Laboratory of Experimental Hematology, CAMS & PUMC, China	1.000000	0.04
Medical University of Lublin, Poland	1.000000	0.04
Maria Sklodowska-Curie National Research Institute of Oncology, Poland	1.000000	0.04
University Medical Center Schleswig-Holstein - Campus Kiel (UKSH Kiel), Germany	1.000000	0.04
Haihe Laboratory of Cell Ecosystem, China	1.000000	0.04
St James's University Hospital, United Kingdom (UK)	1.000000	0.04
GenesisCare UK, United Kingdom (UK)	1.000000	0.04
Vita-Salute San Raffaele University (UniSR), Italy	1.000000	0.04
Willamette Valley Cancer Institute and Research Center (WVCI), United States of America (USA)	1.000000	0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.04
University of Rochester Medical Center (URMC), UR, United States of America (USA)	1.000000	0.04
South-Pest Hospital Centre – National Institute for Infectology and Haematology, PTE, Hungary	1.000000	0.04
University of California, Irvine (UCI), United States of America (USA)	1.000000	0.04
Medical University of Silesia (SUM), Poland	1.000000	0.04
Careggi University Hospital (AOUC), UNIFI, Italy	1.000000	0.04
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.04
Nanfang Hospital, China	1.000000	0.04
Lowy Cancer Research Centre, Australia	1.000000	0.04
Sarah Cannon Research Institute (SCRI), United States of America (USA)	0.500000	0.02
Rocky Mountain Cancer Centers, The US Oncology Network, United States of America (USA)	0.500000	0.02
Vall d'Hebron University Hospital (HUVH), ICS, Spain	0.500000	0.02
Autonomous University of Madrid (UAM), Spain	0.500000	0.02

Interested in Cardiovascular Medicine and Haematology?

Research leaders

2026 Research Leaders

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their output in Nature Index journals in 2025.

Access free

Latest supplement

Nature Index 2026 Nanoscience and nanotechnology

From programmable RNA architectures to next-generation materials for energy and healthcare, researchers are harnessing the unusual properties of the nanoscale to tackle some of society's biggest challenges. This supplement explores the discoveries that are driving the field, the hurdles that remain and the institutions that are leading in nanoscience and nanotechnology research.

Access free

Nature Index 2026 Chemistry

Chemistry research is undergoing a period of transformation, driven by new technologies and mounting environmental pressures. In this supplement, we explore the trends behind China’s extraordinary rise in chemistry output, and why efforts to curb the use of PFASs are accelerating worldwide. We also look at the innovations that could redefine how chemicals are designed, produced and recycled.

Access free

Research highlights of partners

Nonlinear materials add another dimension to light scattering

Institute for Basic Science (IBS)
26 Dec 2023
Overexcitable neurons lead to autistic-like behaviours in mice

Institute for Basic Science (IBS)
30 Nov 2023
How the brain wakes up after anaesthesia

Southern University of Science and Technology (SUSTech)
31 Oct 2023

Research highlights